We welcome Schöllnberger and Kaiser's comments on our review ([@r3]). The biology of radiation-associated athero-sclerosis has been extensively reviewed ([@r1]; [@r4]). As we stated in our paper, there are "biological data suggesting that many inflammatory end points potentially relevant to circulatory disease may be differentially regulated below and above about 0.5 Gy," which is why we studied low-to-moderate exposures ([@r3]). [@r5] and [@r7] support a possible biphasic dose response, as do many other data ([@r1]; [@r4]).

Schöllnberger et al. used multi-model inference ([@r2]) to assess circulatory disease risk in their analysis of the Life Span Study (LSS) cohort of atomic-bomb survivors who were exposed briefly to radiation ([@r8]). We doubt that the effect they observed can be simply generalized to studies of other groups, in particular those chronically exposed. More important, most studies do not have information on potential confounders. We judge that the focus should not be to improve statistical modeling techniques, but to critically address the problems of confounding or other bias and to assess low-dose biological mechanisms.

We also question the validity of the threshold models [@r8] used. No data suggest a threshold for biological markers relevant to circulatory disease ([@r1]; [@r4]).

[@r8] used older LSS data ([@r6]) limited to deaths in proximal survivors since 1968; we judge these restrictions to be questionable for circulatory disease end points. In our analyses ([@r3]), we used current LSS data ([@r9]) that show substantially more deaths (12,139 vs. 3,954 for stroke; 14,018 vs. 4,477 for heart diseases), which means the analysis by [@r8] has much less statistical power and that some of their inferences are likely inconsistent with the current data.

In summary, [@r8]used biologically questionable models fitted to a single, older (LSS) data set, disregarding evidence from radiation-induced circulatory disease risks in several populations with low-to-moderate exposures ([@r3]). It is important to know whether low doses or dose rates of radiation are associated with increased morbidity and premature mortality and, if so, by what mechanism. The point of our paper was to address this clinical and public health concern.
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